Search results
-
J&J ramps up its bladder cancer battle
… +/- cetrelimab vs cetrelimab CR Data at ESMO 2024: CR 84% with TAR-200 mono vs 46% with cetrelimab; … cystectomy + cetrelimab vs cetrelimab pCR Data at ESMO 2024: pCR 42% with TAR-200 + cetrelimab vs 23% with …
- 10/09/2024 - 10:09 -
AbbVie has Met phase 3, again
… ORR in high cMet expressers at doses ≥2.4mg/kg); data at ESMO 2024 in GEA (29% ORR) & NSCLC (44% ORR) Ph1 …
- 02/25/2025 - 10:35 -
Shattuck exits oncology
… PD-(L)1-refractory Hodgkin’s lymphoma (Tevimbra combo) at ESMO 2024: 67% ORR (22/33 pts) Lemzoparlimab I-Mab …
- 10/02/2024 - 10:58 -
ESMO 2024 – Regeneron's fianlimab do-over
ESMO 2024 – Regeneron's fianlimab do-over …
- 09/23/2024 - 21:34 -
ESMO 2024 movers – VEGF bispecifics win, TIGIT loses
ESMO 2024 movers – VEGF bispecifics win, TIGIT loses … degraders in focus Prelude led the biotech fallers, but ESMO 2024 might be better remembered for the latest collapse … September, its last day of formal presentations. ESMO 2024 risers Company Share movement* …
- 09/20/2024 - 15:01 -
ESMO 2024 – Amgen’s PRMT5 still looks lacklustre
ESMO 2024 – Amgen’s PRMT5 still looks lacklustre … 193 in phase 1/2 Triple Meeting 2023 ESMO 2024 presentation Cutoff date 1 Sep 2023 …
- 09/17/2024 - 12:26 -
ESMO 2024 – Bristol abandonment overshadows Immatics
ESMO 2024 – Bristol abandonment overshadows Immatics …
- 09/18/2024 - 16:57 -
ESMO 2024 – Torl challenges BioNTech in Claudin6
ESMO 2024 – Torl challenges BioNTech in Claudin6 … Cross-trial comparison of Claudin-6-targeted projects at ESMO 2024 BNT211 TORL-1-23 DS-9606a …
- 09/17/2024 - 12:26 -
ESMO 2024 – Bristol bucks the degrader trend
ESMO 2024 – Bristol bucks the degrader trend …
- 09/17/2024 - 12:26 -
ESMO 2024 – Astellas defends its degrader
ESMO 2024 – Astellas defends its degrader …
- 10/09/2024 - 14:56
